Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

76.09USD
3:59pm EST
Change (% chg)

$0.21 (+0.28%)
Prev Close
$75.88
Open
$75.86
Day's High
$76.16
Day's Low
$74.26
Volume
3,767,342
Avg. Vol
2,704,240
52-wk High
$86.26
52-wk Low
$63.76

Latest Key Developments (Source: Significant Developments)

Gilead Sciences and Kite To Acquire Cell Design Labs
Thursday, 7 Dec 2017 05:00pm EST 

Dec 7 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND KITE TO ACQUIRE CELL DESIGN LABS.GILEAD SCIENCES INC - DEAL FOR UP TO APPROXIMATELY $567 MILLION.GILEAD SCIENCES INC - AGREEMENT INCLUDES AN INITIAL UPFRONT PAYMENT OF APPROXIMATELY $175 MILLION.GILEAD SCIENCES - DEAL INCLUDES ADDITIONAL PAYMENTS OF UP TO $322 MILLION PAID TO SHAREHOLDERS OF CELL DESIGN LABS OTHER THAN KITE UPON OCCURRENCE OF CERTAIN EVENTS.GILEAD SCIENCES - CO, CELL THERAPY UNIT KITE ANNOUNCED THEY ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH THEY AGREED TO ACQUIRE CELL DESIGN LABS.GILEAD SCIENCES - WILL BUY ALL OF CELL DESIGN LABS' SHARES, WHICH INCLUDES ABOUT 12.2 PERCENT OF SHARES OF CELL DESIGN LABS CURRENTLY HELD BY KITE.  Full Article

X-Chem And Gilead Announce Drug Discovery Collaboration
Tuesday, 28 Nov 2017 08:15am EST 

Nov 28 (Reuters) - Gilead Sciences Inc ::X-CHEM AND GILEAD ANNOUNCE DRUG DISCOVERY COLLABORATION.‍X-CHEM-AS PER AGREEMENT, CO TO SCREEN PROPRIETARY DEX(TM) LIBRARIES TO DISCOVER THERAPEUTIC LEADS AGAINST TARGETS IN ANTIVIRAL, ADDITIONAL THERAPEUTIC AREAS​.X-CHEM- ‍UNDER TERMS ,CO TO RECEIVE UPFRONT PAYMENT, POTENTIAL LICENSING FEES,& ADDITIONAL PAYMENTS.X-CHEM​- GILEAD ‍HAS OPTION TO LICENSE DRUG LEADS DISCOVERED UNDER COLLABORATION, FOR FURTHER DEVELOPMENT, COMMERCIALIZATION OF RESULTING PROGRAMS.  Full Article

Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
Wednesday, 15 Nov 2017 04:30pm EST 

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial.Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​.Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​.Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018.  Full Article

Gilead sciences says post-trial motions judge denied Idenix’S motion for enhanced damages
Tuesday, 7 Nov 2017 06:44am EST 

Nov 7 (Reuters) - Gilead Sciences Inc :Gilead Sciences says in Sept 2017, post-trial motions judge denied Idenix’s motion for enhanced damages and attorney’s fees - SEC filing.Gilead Sciences Inc - expect the judge to rule on outstanding motions with relation to Idenix in late 2017 or early 2018‍​.  Full Article

Gilead announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis
Tuesday, 24 Oct 2017 08:36am EDT 

Oct 24 (Reuters) - Gilead Sciences Inc ::Announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis (NASH).In Phase 2 study, ‍oral ACC inhibitor led to significant reductions in measures of liver fat and fibrosis​.In Phase 2 study, GS-0976 was well-tolerated; nausea, abdominal pain & diarrhea were most common adverse events​.Differences between GS-0976 5 mg and placebo were not statistically significant​.  Full Article

FDA approves Gilead's CAR-T cell therapy
Wednesday, 18 Oct 2017 06:23pm EDT 

Oct 18 (Reuters) - U.S. Food and Drug Administration -:FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma.FDA says granted approval of Yescarta to Kite Pharma Inc.FDA says Yescarta carries a boxed warning for Cytokine release syndrome‍​.FDA says due to risk of CRS and neurologic toxicities, Yescarta is being approved with risk evaluation and mitigation strategy.FDA says it is requiring that hospitals and their associated clinics that dispense Yescarta be specially certified.  Full Article

Kevin Young to retire as Gilead Sciences COO
Wednesday, 27 Sep 2017 08:16pm EDT 

Sept 27 (Reuters) - Gilead Sciences Inc :Kevin Young CBE, chief operating officer, plans to retire, effective early 2018​.Young will remain with Gilead through Q1 of next year and in an advisory capacity thereafter​.  Full Article

Janssen submits new drug application to FDA
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Janssen Research & Development LLC :Janssen submits new drug application to U.S. Food And Drug Administration for the first darunavir-based single tablet regimen for the treatment of HIV-1.Janssen Research & Development - Janssen seeks approval for investigational regimen.  Full Article

China Food and Drug Administration approves Gilead’s Sovaldi
Monday, 25 Sep 2017 07:55am EDT 

Sept 25 (Reuters) - Gilead Sciences Inc :China Food and drug Administration approves Gilead’s Sovaldi (sofosbuvir) for treatment of chronic Hepatitis C virus infection.Gilead Sciences Inc - ‍Sovaldi-based regimens demonstrated high rates of sustained virologic response or cure for Chinese Hepatitis C infected patients​.  Full Article

Gilead Sciences says co entered into a seventh supplemental indenture
Thursday, 21 Sep 2017 04:50pm EDT 

Sept 22 (Reuters) - Gilead Sciences Inc :Gilead Sciences Inc - on September 21, 2017, co entered into a seventh supplemental indenture to indenture between parties, dated as of March 30, 2011.  Full Article

Photo

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.